Fat Atrophy Clinical Trial
Official title:
Clinical Evaluation of the Safety and Efficacy of a 1060 nm Diode Laser for Non-invasive Fat Reduction of the Flanks
NCT number | NCT03756168 |
Other study ID # | CS0518 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 14, 2018 |
Est. completion date | July 2, 2019 |
Verified date | January 2024 |
Source | Venus Concept |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this clinical study is to assess the safety and efficacy of using a 1060 nm diode laser for non-invasive fat reduction of the flanks.
Status | Completed |
Enrollment | 30 |
Est. completion date | July 2, 2019 |
Est. primary completion date | July 2, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - able to read, understand and voluntarily provide written informed consent - healthy male or female > 18 years of age seeking treatment for unwanted fat in the abdomen - BMI score is less then 30 - agree to not making any major changes in their diet or lifestyle during the course of the study - able and willing to comply with the treatment / follow up schedule and requirements - women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrolment and for the duration of the study, have a negative urine pregnancy test baseline Exclusion Criteria: - pregnant in the last 3 months intending to become pregnant, postpartum or nursing in the last 6 months - any previous liposuction / lipo-sculpture or any type of surgical procedure in the treatment area in the past 12 months - history of immunosuppression / immune deficiency disorders including AIDS and HIV infection, or use of immunosuppressive medications, 6 month prior to and during the course of the study - History of hyperlipidemia, diabetes, hepatitis, blood coagulopathy or excessive bleeding - Use of antiplatelet medications (81 mg of acetylsalicylic acid daily is permitted), anticoagulants, thrombocytes or any-inflammatory medications within 2 weeks of treatment - Having a history of skin cancer or any other cancer in the area to be treated, including presence of malignant or pre-malignant pigmented lesions - Having a permanent implant in the treatment area such as a metal plate or injected chemical substance such as silicone pr parenteral gold therapy (gold sodium thiomalate) - Use of medications, herbs or food supplements and vitamins known to induce photosensitivity to light exposure at the wavelength used history of photosensitivity disorder - Suffering from significant skin conditions in the treatment area or inflammatory skin conditions including but not limited to open lacerations, abrasions, herpes sores, cold sores, active infections - Tattoos in the treatment area - Poor quality skin (laxity) - Abdominal wall, muscular abnormality or hernia on physical examination - Unstable weight within the last 6 months (+ or - 3% weight change in the prior six months) - Participation in another clinical study involving the same anatomical areas within the last 6 months - History of keloid and hypertrophic scar formation or poor wound healing in the treatment area - As per the investigators discretion any physician or mental condition which may make it unsafe for the subject to participate |
Country | Name | City | State |
---|---|---|---|
United States | UT Southwestern Medical Centre | Dallas | Texas |
United States | Laser and Skin Surgery Center of Northern California | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
Venus Concept |
United States,
Kang A, Kislevitz M, Wamsley C, Barillas J, Hoopman J, Kenkel J, Kilmer S. Clinical evaluation of the safety and efficacy of a 1060 nm diode laser for non-invasive fat reduction of the flanks. J Cosmet Dermatol. 2023 Nov;22(11):3017-3025. doi: 10.1111/joc — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the Percentage of Fat Thickness From Baseline to 12-weeks Post-treatment | Change in the percentage of fat thickness of the adipose layer as measured by ultrasound at 12 weeks post-treatment as compared to baseline. | Week 12 | |
Secondary | Change in Abdominal Circumference From Baseline to 12 Weeks Post-treatment | Change in the abdominal circumference at 12 weeks post-treatment as compared to baseline | Week 12 | |
Secondary | Subject Satisfaction | Subject satisfaction with treatment at 12 weeks was assessed using the 5-point Likert subject satisfaction scale. 5 is very satisfied, while 1 is very unsatisfied | Week 12 | |
Secondary | Treatment Pain | Treatment pain assessed immediately post-treatment as measured using the Wong-Baker Faces Scale. Pain was measured on a scale from 0-10 (10 worst pain ever, to 0 no pain at all) | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03756350 -
Clinical Evaluation of the Safety and Efficacy of a 1060nm Diode Laser (Abdomen)
|
N/A | |
Not yet recruiting |
NCT05318716 -
The Fat Analysis Trial (FAT) - Assessing the Impact of Lipo-aspirate Processing
|
N/A |